Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2013 (2013), Article ID 418565, 5 pages
http://dx.doi.org/10.1155/2013/418565
Case Report

Heart Transplantation in a 14-Year-Old Boy in the Presence of Severe Out-of-Proportion Pulmonary Hypertension due to Restrictive Left Heart Disease: A Case Report

1Department of Pediatrics, Division of Cardiology, Pulmology, Allergology and Cystic Fibrosis, Innsbruck Medical University, 6020 Innsbruck, Austria
2Department of Pediatrics, Pediatric Intensive Care Unit, Innsbruck Medical University, 6020 Innsbruck, Austria
3Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, 6020 Innsbruck, Austria
4Department of Pediatric Cardiology, Medical University of Vienna, 1090 Vienna, Austria
5Department of Pediatrics, Salzburg State Hospital, 5020 Salzburg, Austria
6Department of Pathology, Innsbruck Medical University, 6020 Innsbruck, Austria

Received 28 February 2013; Accepted 25 March 2013

Academic Editors: C. D. Barrett and A. Movahed

Copyright © 2013 Martin Schwienbacher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. M. Steger, H. Antretter, and P. L. Moser, “Endocardial fibroelastosis of the heart,” The Lancet, vol. 379, no. 9819, 932 pages, 2012. View at Publisher · View at Google Scholar
  2. J. D. Robinson, P. J. Del Nido, R. L. Geggel, A. R. Perez-Atayde, J. E. Lock, and A. J. Powell, “Left ventricular diastolic heart failure in teenagers who underwent balloon aortic valvuloplasty in early infancy,” American Journal of Cardiology, vol. 106, no. 3, pp. 426–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. O. Reich, P. Tax, J. Marek et al., “Long term results of percutaneous balloon valvoplasty of congenital aortic stenosis: independent predictors of outcome,” Heart, vol. 90, no. 1, pp. 70–76, 2004. View at Google Scholar · View at Scopus
  4. G. Simonneau, I. M. Robbins, M. Beghetti et al., “Updated clinical classification of pulmonary hypertension,” Journal of the American College of Cardiology, vol. 54, no. 1, supplement 1, pp. S43–S54, 2009. View at Publisher · View at Google Scholar
  5. R. L. Benza and J. A. Tallaj, “Pulmonary hypertension out of proportion to left heart disease,” Advances in Pulmonary Hypertension, vol. 5, no. 1, pp. 21–29, 2006. View at Google Scholar
  6. J. K. Kirklin, D. C. Naftel, J. W. Kirklin, E. H. Blackstone, C. White-Williams, and R. C. Bourge, “Pulmonary vascular resistance and the risk of heart transplantation,” Journal of Heart Transplantation, vol. 7, no. 5, pp. 331–336, 1988. View at Google Scholar · View at Scopus
  7. O. Nallet, O. Milleron, F. Monsel, B. Safar, I. Ghrissi, and J. Sergent, “Pulmonary hypertension and heart failure: the role of pulmonary vasculature,” Annales de Cardiologie et d'Angeiologie, vol. 58, no. 5, pp. 304–309, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Trautnitz, S. Pehlivanli, J. Behr et al., “Pharmacological testing of the reversibility of increased pulmonary vascular resistance before heart transplantation with prostaglandin I2 (prostacyclin),” Zeitschrift für Kardiologie, vol. 88, pp. 133–140, 1999 (German). View at Publisher · View at Google Scholar
  9. S. M. Emani, E. A. Bacha, D. B. McElhinney et al., “Primary left ventricular rehabilitation is effective in maintaining two-ventricle physiology in the borderline left heart,” Journal of Thoracic and Cardiovascular Surgery, vol. 138, no. 6, pp. 1276–1282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Haikala, J. Kaivola, E. Nissinen, P. Wall, J. Levijoki, and I. B. Linden, “Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan,” Journal of Molecular and Cellular Cardiology, vol. 27, no. 9, pp. 1859–1866, 1995. View at Google Scholar · View at Scopus
  11. F. Follath, “Newer treatments of decompensated heart failure: focus on levosimendan,” Journal of Drug Design, Development and Therapy, vol. 3, pp. 73–78, 2009. View at Publisher · View at Google Scholar
  12. H. Tachibana, H.-J. Cheng, T. Ukai et al., “Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure,” American Journal of Physiology, vol. 288, no. 2, pp. H914–H922, 2005. View at Publisher · View at Google Scholar
  13. H. Yokoshiki, Y. Katsube, M. Sunagawa, and N. Spereulkis, “The novel calcium sensitizer levosimendan activates the ATP-sensitive K+-channel in rat ventricular cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 283, no. 1, pp. 375–383, 1997. View at Google Scholar · View at Scopus
  14. S. Rehberg, C. Ertmer, H. Van Aken et al., “Role of levosimendan in intensive care treatment of myocardial insufficiency,” Anaesthesist, vol. 56, no. 1, pp. 30–43, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. S. Nieminen, J. Akkila, G. Hasenfuss et al., “Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure,” Journal of the American College of Cardiology, vol. 36, no. 6, pp. 1903–1912, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. M. T. Slawsky, W. S. Colucci, S. S. Gottlieb et al., “Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure,” Circulation, vol. 102, no. 18, pp. 2222–2227, 2000. View at Google Scholar · View at Scopus
  17. H. A. Leather, K. Ver Eycken, P. Segers, P. Herijgers, E. Vandermeersch, and P. F. Wouters, “Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs,” Critical Care Medicine, vol. 31, no. 9, pp. 2339–2343, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Ukkonen, M. Saraste, J. Akkila et al., “Myocardial efficiency during levosimendan infusion in congestive heart failure,” Clinical Pharmacology and Therapeutics, vol. 68, no. 5, pp. 522–531, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Grander, P. Eller, J. Gänzer, H. Tilg, and R. Geiger, “Bosentan treatment in chronic pulmonary venous hypertension with significant right heart dysfunction,” Current Medical Research and Opinion, vol. 23, no. 2, pp. S71–S76, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Murali, B. F. Uretsky, P. S. Reddy, T. R. Tokarczyk, and A. R. Betschart, “Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents,” American Heart Journal, vol. 122, no. 5, pp. 1375–1381, 1991. View at Publisher · View at Google Scholar · View at Scopus
  21. A. E. Lammers, A. A. Hislop, Y. Flynn, and S. G. Haworth, “Epoprostenol treatment in children with severe pulmonary hypertension,” Heart, vol. 93, no. 6, pp. 739–743, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Perez-Villa, A. Cuppoletti, V. Rossel, I. Vallejos, and E. Roig, “Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension,” Clinical Transplantation, vol. 20, no. 2, pp. 239–244, 2006. View at Publisher · View at Google Scholar · View at Scopus